Smith & Nephew plc Stock Rating Reaffirmed by Berenberg Bank (SNN)
Several other analysts have also recently commented on the stock. Analysts at Morgan Stanley downgraded shares of Smith & Nephew plc from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 15th. Separately, analysts at Panmure Gordon reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. Finally, analysts at Numis Securities Ltd reiterated a “hold” rating on shares of Smith & Nephew plc in a research note on Monday, August 4th. Nine research analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The company currently has a consensus rating of “Hold” and an average price target of $97.00.
Smith & Nephew plc (NYSE:SNN) traded down 1.64% during mid-day trading on Tuesday, hitting $86.88. 78,124 shares of the company’s stock traded hands. Smith & Nephew plc has a 52-week low of $57.99 and a 52-week high of $100.90. The stock has a 50-day moving average of $87.6 and a 200-day moving average of $82.46. The company has a market cap of $15.534 billion and a price-to-earnings ratio of 30.41.
Smith & Nephew plc (NYSE:SNN) last posted its quarterly earnings results on Friday, August 1st. The company reported $1.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.08. On average, analysts predict that Smith & Nephew plc will post $4.21 earnings per share for the current fiscal year.
Smith & Nephew plc is a global medical devices business operating in the markets for orthopaedic reconstruction and trauma, endoscopy (NYSE:SNN) and advanced wound management.
Receive News & Ratings for Smith & Nephew plc (ADR) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew plc (ADR) and related companies with Analyst Ratings Network's FREE daily email newsletter.